Trial Profile
Pilot study of immune response to human papillomavirus vaccine in patients with inflammatory bowel disease receiving immunosuppressants
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Dec 2015
Price :
$35
*
At a glance
- Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
- Indications Cervical cancer; Human papillomavirus infections
- Focus Pharmacodynamics
- 16 Dec 2015 New trial record